World

Mexico sees fake molnupiravir a week after the drug is approved

Mexico City: Mexico saw a black market or fake Molnupiravir for sale on Friday, just a week after authorities approved a drug to treat people at risk for severe COVID-19. He said he had already seen it.

The actual drug is manufactured by the US pharmaceutical company Merck. However, Mexican health regulators have found a version labeled Molnupiravir for sale by a range of companies such as Merit, Moraz, and Azista.

Authorities said Friday that there were no records of licenses to import or sell these companies’ medicines and believe they pose a health risk.

The Federal Health Protection Commission writes that because molnupiravir is only approved for the use of prescription drugs, products advertised as molnupiravir on the market should be considered a health risk due to their questionable origin. ..

Last week, the Mexican government approved Merck’s Molnupiravir for COVID-19 in adults at high risk of complications. On Friday, the agency approved Paxlovid, a second tablet from Pfizer, for use in adult patients at risk of complications.

Mexico has long been plagued by counterfeit medicines, corruption within regulatory agencies, and a tendency for self-medication due to the country’s inadequate medical infrastructure.

In this country, apparently due to Omicron variants, coronavirus cases surged by more than 200% last week and are under-tested, tending to drive consumers to the black market.

Mexico has rarely tested, so only about 300,000 deaths from COVID-19 have been confirmed in the test, but a government review of death certificates shows that the actual number of deaths is about 460,000. ..

Disclaimer: This post is auto-published from the agency feed without modification of the text and has not been reviewed by the editor.

Read all the latest news, latest news, coronavirus news here.

Mexico sees fake molnupiravir a week after the drug is approved

Source link Mexico sees fake molnupiravir a week after the drug is approved

Related Articles

Back to top button